Inventor · disambiguated record
Christopher Lincoln
Also filed as: LINCOLN CHRISTOPHER
11 granted patents·1 pending application·48 citations·filing 2000–2018
87Inventor score
Files withHOPE CITY11
Top patents by PatentIndex Score
12 records- 0194US9828342B2Isatin derivatives, pharmaceutical compositions thereof, and methods of use thereofHOPE CITY·Filed 2013·Granted Nov 28, 2017·19 cites·8 claims
- 0288US9126960B2Ribonucleotide reductase inhibitors and methods of useHOPE CITY·Filed 2014·Granted Sep 8, 2015·4 cites·13 claims
- 0388US8372983B2Ribonucleotide reductase inhibitors and methods of useHOPE CITY·Filed 2012·Granted Feb 12, 2013·7 cites·2 claims
- 0485USRE45020ERibonucleotide reductase inhibitors and methods of useHOPE CITY·Filed 2013·Granted Jul 15, 2014·5 cites·2 claims
- 0578US9796692B2Ribonucleotide reductase inhibitors and methods of useHOPE CITY·Filed 2017·Granted Oct 24, 2017·1 cites·19 claims
- 0678US9598385B2Ribonucleotide reductase inhibitors and methods of useHOPE CITY·Filed 2015·Granted Mar 21, 2017·2 cites·20 claims
- 0771US6494942B1Dye-based ink jet compositions having improved stability and light fastnessFiled 2000·Granted Dec 17, 2002·10 cites·36 claims
- 0869US10155732B2Ribonucleotide reductase inhibitors and methods of useHOPE CITY·Filed 2017·Granted Dec 18, 2018·0 cites·20 claims
- 0966US2019161461A1Ribonucleotide reductase inhibitors and methods of useHOPE CITY·Filed 2018·Application pending·0 cites
- 1059US11583509B2Compound for treating cancer and diabetesHOPE CITY·Filed 2017·Granted Feb 21, 2023·0 cites·12 claims
- 1156US9808434B2Compound for treating cancer and diabetesHOPE CITY·Filed 2016·Granted Nov 7, 2017·0 cites·16 claims
- 1254US10029991B2Modulators of development of adipocyte and cancer cellsHOPE CITY·Filed 2013·Granted Jul 24, 2018·0 cites·6 claims
Join the waitlist — get patent alerts
Get an alert when Christopher Lincoln files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →